Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07829185

Title field or adapter rule

{'original_value': 'Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:25.360751+00:00

Published At

2026-09-18T00:00:00+00:00

Record Updated At

2026-09-18

Source Retrieved At

2026-10-31T22:17:56.788771+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Pancreatic Ductal Adenocarcinoma (PDAC)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-09-18", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07829185"

protocolSection.identificationModule.officialTitle

"Modified FOLFIRINOX and Pentamidine as First-line Treatment in Advanced and Metastatic Pancreatic Ductal Adenocarcinoma"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['modified FOLFIRINOX', 'modified FOLFIRINOX + Pentamidine'], 'description': 'In Arm A (up to 15 patients) will be treated with modified FOLFIRINOX every two weeks, delivered as follows:\n\n* Oxaliplatin 85mg/m2 IV over 2 hours on Day 1, followed by,\n* Irinotecan 150mg/m2 IV over 90 minutes on Day 1, followed by\n* Leucovorin 400mg/m2 IV over 2 hours on Day 1, followed by\n* 5FU 2400mg/m2 IV over 46-48 hours on Days 1-3', 'name': 'modified FOLFIRINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['modified FOLFIRINOX + Pentamidine'], 'description': 'In arm B patients (up to 15), the same modified FOLFIRINOX regimen will be used, as above, plus 300 mg pentamidine will be administered IV over a one-hour infusion on Day 1 of each cycle.', 'name': 'Pentamidine 300 MG Injection', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• modified FOLFIRINOX (protocolSection.armsInterventionsModule.interventions[].name)
• Pentamidine 300 MG Injection (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.